BeiGene
BGNE
#961
Rank
A$32.54 B
Marketcap
$297.43
Share price
0.49%
Change (1 day)
16.13%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total assets

Total assets on the balance sheet as of September 2024 : A$9.38 Billion

According to BeiGene 's latest financial reports the company's total assets are A$9.38 Billion. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

BeiGene - Total assets on balance sheet (from 2014 to 2024)

Total assets by year

Year Total assets Change
2023-12-31A$8.52 B-9.1%
2022-12-31A$9.37 B-20.38%
2021-12-31A$11.77 B61.64%
2020-12-31A$7.28 B216.3%
2019-12-31A$2.30 B-27.89%
2018-12-31A$3.19 B138.24%
2017-12-31A$1.34 B138.09%
2016-12-31A$0.56 B251.25%
2015-12-31A$0.16 B144.63%
2014-12-31A$65.51 M395.36%
2013-12-31A$13.22 M

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
A$29.26 M-99.69%๐Ÿ‡บ๐Ÿ‡ธ USA
A$3.63 B-61.31%๐Ÿ‡บ๐Ÿ‡ธ USA